ALSUntangled says Precision Stem Cell protocols need clearer evidence and oversight
Original source
Precision Stem Cell (opens in a new tab)ALSUntangled reviewed Precision Stem Cell (PSC) stem-cell treatments for people with ALS. It found that the protocols were poorly described and appeared to vary in the cell sources, modifications and injection sites. Reported improvements were subjective and usually brief, and the review called for transparent protocols and objective outcome measures before further treatment use.
Why this matters
This is relevant to people considering PSC treatments, because the review identified unanswered questions about what is being injected and how outcomes are assessed. It supports further study of mesenchymal stem cells, but does not establish that PSC treatment is effective or that it should change current treatment decisions.
Limitations and context
This is an independent expert review published by ALSUntangled in 2016, not a report of a controlled clinical trial. The review said the available reports lacked confirmation of the transplanted material and relied on subjective outcomes. Its conclusions concern the specific PSC protocols reviewed and should not be applied to all mesenchymal stem-cell research.